+2 year(s) experience
Zachary McLellan is an Oncology analyst specializing in the coverage of prostate, ovarian, and breast cancers. He focuses on current market developments and treatment trends, as well as indication-specific market and drug forecasting. As an Analyst, Zachary shares his insights through individualized reports, direct client interactions, and Datamonitor Healthcare's online platform. He has also represented Datamonitor Healthcare at the 2016 ASCO conference. His conference coverage included timely analysis through bespoke reports and a live webinar that was attended by clients, prospective clients, investors and other interested parties.
Zachary joined Informa in June 2015 while completing an MSc in Biotechnology and Entrepreneurship from New York University. Prior to Informa, he worked as a chemist.
Zachary Writes For
By Zachary McLellan 02 Jul 2015
On 29 June 2015, Celgene and Juno Therapeutics announced a global collaboration for the development and commercialization of chimeric antigen receptor T cells (CAR-T) and T-cell receptor
Topics Cell and gene therapy